Non-CHO cell expression systems gain traction as faster, more flexible alternatives for biologics manufacturing.

To further complicate clinicians’ treatment decisions, Padcev-Keytruda has become the new standard of care in first-line metastatic bladder cancer, raising the possibility that some physicians might ...

Cas9, Transcription Activator-Like Effector Nucleases (TALENs), and Zinc-Finger nucleases (ZFNs) have demonstrated great utility, primarily for genetic knock-out applications, none have been adopted ...

Once the active ingredient is defined, an Applicant must select which patent, or patents, to put forward for extension. The statute permits only one PTE per regulatory review period, so the choice is ...

Discover the transformation of antibody-drug conjugates (ADCs) from experimental to essential in cancer therapy with new ...

Designing modular, automated vial fill-finish lines that balance high-output demands with small-batch precision in an Annex 1 ...

The world’s female population spends 25% more of their lives in poor health than men do Read more at The Business Times.

Advances in instrumentation, modeling and control are more fully understood and utilized when assisted by first-principle, ...

Discover the critical bioanalytical factors that influence radiopharmaceutical drug development, from assay design to ...

Editor’s note: This round‑up is based on press releases, peer‑reviewed publications, and company communications received in January and February 2026. All results are preliminary unless stated, and ...

Q4 2025 Earnings Call February 24, 2026 4:30 PM ESTCompany ParticipantsAndrew Guggenhime - President & CFOGrant Pickering ...

Virginia attracted $12 billion in pharmaceutical manufacturing investments in 2025, leveraging site readiness, workforce training, and strong infrastructure.